Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 03, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically regarding the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details specific share movements on September 27, 2005, involving the SmithKline Beecham Employee Benefit Trust:
- Shares Sold: 237 Ordinary shares were sold on behalf of a participant in the GlaxoSmithKline Annual Investment Plan at a price of GBP 14.3236 per share.
- Shares Transferred: 770 Ordinary shares were transferred from the Trust to a participant in the GlaxoSmithKline Annual Investment Plan.
Director Mr. J. Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the significance of the 237 shares sold and 770 shares transferred.
- Confirm the current share price relative to the transaction price of GBP 14.3236 per share.
- Review the full composition of the Trust to understand the scope of Director Mr. J. Heslop's indirect interest.